Compare LXU & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LXU | DBVT |
|---|---|---|
| Founded | 1968 | 2002 |
| Country | United States | France |
| Employees | 513 | 90 |
| Industry | Major Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | 2006 | 2014 |
| Metric | LXU | DBVT |
|---|---|---|
| Price | $14.82 | $20.94 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 7 |
| Target Price | $14.63 | ★ $32.04 |
| AVG Volume (30 Days) | ★ 1.5M | 228.8K |
| Earning Date | 04-29-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 225.93 | 10.26 |
| EPS | ★ 0.34 | N/A |
| Revenue | ★ $615,208,000.00 | $5,636,000.00 |
| Revenue This Year | $13.69 | $35.04 |
| Revenue Next Year | N/A | $2,360.78 |
| P/E Ratio | $42.91 | ★ N/A |
| Revenue Growth | 17.77 | ★ 35.77 |
| 52 Week Low | $5.86 | $7.53 |
| 52 Week High | $17.22 | $26.19 |
| Indicator | LXU | DBVT |
|---|---|---|
| Relative Strength Index (RSI) | 54.48 | 51.02 |
| Support Level | $7.92 | $20.23 |
| Resistance Level | $15.66 | $23.52 |
| Average True Range (ATR) | 0.74 | 0.89 |
| MACD | -0.05 | -0.05 |
| Stochastic Oscillator | 76.22 | 41.41 |
LSB Industries Inc is engaged in the manufacturing and sale of chemical products in the United States. The company manufactures and sells chemical products for the agricultural and industrial sectors. Its products include ammonia, fertilizer grade ammonium nitrate (AN and HDAN), and urea ammonia nitrate (UAN) for agricultural applications; high purity and commercial grade ammonia, sulfuric acids, concentrated, blended, and regular nitric acid, mixed nitrating acids, carbon dioxide, and diesel exhaust fluid for industrial applications; and industrial grade AN (LDAN) and AN solutions for mining applications. Its products are sold through distributors and directly to end customers throughout the United States and other parts of North America.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.